Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer. But for patients to benefit, they must have access to robust biomarker testing capabilities, a challenge in many community cancer settings. Yet this testing is time-consuming and costly to outsource.

 

The solution? Canexia Health can help your lab deploy cancer genomics assays at a fraction of the cost of outsourcing multigene panels to a centralized lab, and without the need to invest in a costly bioinformatics infrastructure. 

 

Our Clinical Services team supports labs with bringing precision oncology programs in-house, including the implementation and maintenance of clinical next-generation sequencing-based profiling.

 

Watch our video to learn how we can help you deliver on your mandate for providing best-in-class cancer care.

Back

Recent Resources

Blog

August 10, 2021

Increasing Access to Circulating Tumor DNA Testing in Canada: Webinar

Cancer patients have been heavily impacted by the ongoing COVID-19 pandemic. With thousands of tissue biopsies delayed and patients postponing clinic visits across Canada, increasing access to circulating tumour DNA (ctDNA) testing for targeted treatment selection has offered another option for oncologists.